PRTA实时信号 | 通过Getagraph.com最大化利润

购买 107294 min ago

@ $27.01

发出时间: 15 Feb 2024 @ 04:42

回报率: -22.73%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -1.57 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States...

Stats
今日成交量	369 176
平均成交量	653 771
市值	1.12B
EPS	$0 ( 2024-02-15 )
下一个收益日期	( $-1.210 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.56
ATR14	$0.0210 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Ford David A	Buy	85 000	Stock Option (Right to Buy)
2024-03-01	Ford David A	Buy	0
2024-02-27	Zago Wagner M.	Buy	85 000	Stock Option (Right to Buy)
2024-02-27	Walker Karin L	Buy	54 000	Stock Option (Right to Buy)
2024-02-27	Smith Brandon S.	Buy	85 000	Stock Option (Right to Buy)

INSIDER POWER
77.71
Last 98 transactions
Buy: 1 184 000 \| Sell: 192 000

音量相关性

長: -0.18 (neutral)

短: -0.49 (neutral)

Signal:(51.622) Neutral

Prothena Corporation PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Prothena Corporation PLC 相关性 - 货币/商品

-0.60
( weak negative )

-0.62
( weak negative )

0.00
( neutral )

-0.51
( weak negative )

-0.09
( neutral )

0.34
( neutral )

Prothena Corporation PLC 财务报表

Annual	2023
营收:	$91.37M
毛利润:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2023
营收:	$91.37M
毛利润:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2022
营收:	$53.91M
毛利润:	$47.16M (87.49 %)
EPS:	$-2.47

FY	2021
营收:	$200.58M
毛利润:	$0.00 (0.00 %)
EPS:	$1.510

Financial Reports:

No articles found.

Prothena Corporation PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

实时更新： Prothena Corporation PLC [PRTA]

Upcoming Earnings Alert